Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Core Insights - The company is advancing its clinical pipeline, particularly focusing on isaralgagene civaparvovec for Fabry disease, with a meeting held with the FDA to discuss the use of eGFR slope as an endpoint for accelerated approval [1][12] - The registrational STAAR study has shown promising clinical data, indicating that isaralgagene civaparvovec may provide durable treatment benefits for Fabry disease, with patient recruitment ongoing for the Phase 1/2 STAND study in chronic neuropathic pain [2][4] - Financial results for Q3 2025 show a significant decrease in revenues and a net loss, with total revenues of $0.6 million compared to $49.4 million in Q3 2024, primarily due to a collaboration agreement with Genentech recorded in the previous year [9][10] Clinical Developments - The STAAR study reported a positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year at 52 weeks across 32 patients, indicating the treatment's effectiveness [6] - Improvements in disease severity were noted, with 22 patients showing enhancements in their total MSSI score at 12 months [7] - The company is preparing for a potential Biologics License Agreement (BLA) submission for isaralgagene civaparvovec as early as Q1 2026 [12] Financial Performance - The consolidated net loss for Q3 2025 was $34.9 million, or $0.11 per share, compared to a net income of $10.7 million, or $0.04 per share, in Q3 2024 [9][29] - Total operating expenses for Q3 2025 were $36.1 million, a decrease from $38.8 million in the same period in 2024, driven by lower personnel costs and licensing expenses [13][14] - As of September 30, 2025, cash and cash equivalents stood at $29.6 million, down from $41.9 million at the end of 2024, with expectations to fund operations into Q1 2026 [15][30] Regulatory and Corporate Updates - The company held a productive interaction with the Medicines and Healthcare products Regulatory Agency (MHRA) regarding a prion disease study, anticipating a Clinical Trial Application (CTA) submission [3][12] - A $6 million payment was received from Pfizer for a buyout option related to a 2008 license agreement, enhancing the company's financial position [6] - The company continues to focus on establishing partnerships for the commercialization of its Fabry disease program while advancing its neurology pipeline [17][21]